NCT01149356: RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer |
|
|
| Terminated | 1 | 15 | US | Exemestane, Aromasin, FCE-24304, Gamma-Secretase Inhibitor RO4929097, RO4929097, Goserelin Acetate, ZDX, Zoladex | National Cancer Institute (NCI) | Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer | 12/12 | 04/13 | | |
NCT01240928: MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer |
|
|
| Withdrawn | 1 | 0 | US | MSK-2206, Exemestane, Goserelin | Vanderbilt-Ingram Cancer Center | Metastatic Breast Cancer | | | | |
